DiscernDx has reported that preliminary study results from its non-invasive liquid biopsy test for diagnosing early stages of nonalcoholic steatohepatitis (NASH) showed the multi-omics and machine learning combination for NASH diagnosis as an alternative to liver biopsy.

Blood samples were collected from 29 centres across the US and Canada forming a cohort of 517 patients suspected of having NASH F2-F4 fibrosis grades.

The liquid biopsy test’s preliminary performance characterised by the area under the receiver operating characteristic (AUROC) in the development set of 90 samples showed exceptional performance in reproducing liver biopsy results, with an AUROC of 0.92.

DiscernDx noted that the liquid biopsy test could be an accurate and non-invasive substitute for liver biopsy for patients suspected of having NASH in the US.

It could lower the requirement for liver biopsy and costly imaging and could aid in earlier disease diagnosis and clinical trials for NASH treatments.

DiscernDx CEO Chris Hall said: “We’re excited to present this data for the first time, as there is a huge unmet medical need for a highly accurate, non-invasive test for early detection of liver fibrosis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Our non-invasive, potentially first-to-market liquid biopsy test is able to diagnose NASH with significant fibrosis with high accuracy, which is critical to avoid unnecessary liver biopsy for patients.”

A progressive and prevalent liver disease, nonalcoholic fatty liver disease (NAFLD) affects around a quarter of adults in the US.

Approximately 20% of NAFLD patients advance to NASH, which can progress into liver cirrhosis. By 2030, it is estimated to be the most frequent cause of liver transplants.

Major predictors of outcomes in NAFLD are liver fibrosis development and progression.